SHINVA(600587)2025-04-29 12:18Financial Performance - The company's operating revenue for Q1 2025 was ¥2,307,531,823.28, a decrease of 8.74% compared to ¥2,528,538,840.43 in the same period last year[4]. - Net profit attributable to shareholders was ¥160,455,800.07, down 23.97% from ¥211,036,820.12 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥157,702,901.57, reflecting a decline of 24.53% compared to ¥208,965,933.49 in the previous year[4]. - The basic and diluted earnings per share were both ¥0.27, a decrease of 22.86% from ¥0.35 in the same period last year[4]. - The weighted average return on equity decreased to 2.09%, down 0.78 percentage points from 2.87% year-on-year[4]. - Total operating revenue for Q1 2025 was CNY 2,307,531,823.28, a decrease of 8.7% from CNY 2,528,538,840.43 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 161,227,589.00, a decline of 25.1% compared to CNY 215,024,150.02 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, down from CNY 0.35 in Q1 2024[20]. - The company reported a total comprehensive income of CNY 161,227,589.00 for Q1 2025, compared to CNY 215,024,150.02 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,324,351,008.59, a decrease of 1.30% from ¥15,526,375,082.77 at the end of the previous year[5]. - The company's current assets totaled CNY 9,059,086,874.27, down from CNY 9,366,020,874.15, indicating a decrease of about 3.3%[14]. - The total liabilities decreased to CNY 6,848,384,341.13 from CNY 7,237,038,074.90, reflecting a reduction of approximately 5.4%[15]. - Total liabilities amounted to CNY 7,155,288,798.36, a decrease from CNY 7,543,748,934.23 in the previous period[16]. - The company's long-term equity investments increased to CNY 1,518,261,716.52 from CNY 1,506,671,275.58, reflecting a growth of about 0.8%[15]. - The total current liabilities amounted to CNY 6,848,384,341.13, which is a significant portion of the total liabilities[15]. Cash Flow - The net cash flow from operating activities was -¥163,624,921.28, an improvement from -¥213,902,750.72 in the same period last year[4]. - Cash received from sales of goods and services in Q1 2025 was CNY 2,039,406,999.49, a slight decrease from CNY 2,070,468,159.18 in Q1 2024[22]. - The net cash flow from operating activities was -$163.62 million, compared to -$213.90 million in the previous period, indicating an improvement of approximately 23.5%[23]. - Total cash inflow from operating activities was $2.11 billion, while cash outflow was $2.28 billion, resulting in a net cash flow of -$163.62 million[23]. - Cash inflow from investment activities was $1.45 million, while cash outflow was $187.67 million, leading to a net cash flow of -$186.21 million[23]. - Cash inflow from financing activities was $455.10 million, with cash outflow totaling $432.62 million, resulting in a net cash flow of $22.48 million[24]. - The total cash and cash equivalents at the end of the period was $2.44 billion, down from $2.65 billion in the previous period[24]. - Payments to employees amounted to $514.46 million, reflecting a decrease from $537.90 million in the previous period[23]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.50% to ¥7,786,792,401.82 from ¥7,597,127,229.99 at the end of the previous year[5]. - Total equity attributable to shareholders increased to CNY 7,786,792,401.82 from CNY 7,597,127,229.99[16]. Operational Insights - The decline in revenue was primarily due to decreased sales in the medical trading segment[8]. - The company reported non-recurring gains of ¥2,752,898.50, after accounting for tax and minority interests[8]. - Research and development expenses increased to CNY 93,857,263.18 in Q1 2025, up from CNY 83,305,119.71 in Q1 2024, reflecting a focus on innovation[19]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[12]. Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25].